1. Home
  2. BTDR vs ACAD Comparison

BTDR vs ACAD Comparison

Compare BTDR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTDR

Bitdeer Technologies Group

HOLD

Current Price

$12.25

Market Cap

3.7B

Sector

Technology

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$25.47

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTDR
ACAD
Founded
2021
1993
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.8B
IPO Year
2021
2000

Fundamental Metrics

Financial Performance
Metric
BTDR
ACAD
Price
$12.25
$25.47
Analyst Decision
Strong Buy
Buy
Analyst Count
10
22
Target Price
$22.70
$30.55
AVG Volume (30 Days)
9.7M
1.9M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
N/A
0.02
Revenue
N/A
$726,437,000.00
Revenue This Year
$72.51
$18.80
Revenue Next Year
$40.84
$11.70
P/E Ratio
N/A
$1,311.00
Revenue Growth
N/A
40.45
52 Week Low
$7.04
$19.69
52 Week High
$27.80
$28.35

Technical Indicators

Market Signals
Indicator
BTDR
ACAD
Relative Strength Index (RSI) 36.26 63.63
Support Level $12.20 $25.40
Resistance Level $12.86 $27.79
Average True Range (ATR) 1.78 0.92
MACD -0.50 0.13
Stochastic Oscillator 4.18 65.38

Price Performance

Historical Comparison
BTDR
ACAD

About BTDR Bitdeer Technologies Group

Bitdeer Technologies Group is principally engaged in the provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: